Facts Matter (Feb. 9): Pfizer Quietly Adds Warning That ‘Unfavorable Pre-Clinical, Clinical, or Safety Data’ May Impact Business

Roman Balmakov
By Roman Balmakov
February 9, 2022Facts Matter
share

As we get closer and closer to the day that the FDA has to release its first batch of 55,000 pages of clinical trial documents, it looks like Pfizer is bracing for impact.

That’s because it was just revealed that Pfizer updated its fourth-quarter investor report—the section on potential risks to their business.

Specifically, they added that in the near future, information regarding the quality of pre-clinical, clinical, or safety data that might be released by an audit or inspection might be a threat to their business.

Meanwhile, while I was in Texas, I took the opportunity to sit down and speak with Jim Lamon, the founder of an America-first renewable energy company, and we discussed the way forward for American energy independence.

Resources:

American Hartford Gold (866-242-2352):

https://ept.ms/3biH9MN

Pfizer:

https://ept.ms/3rEi6f3

Q4 Report:

https://ept.ms/3rGlJRQ

Q3 Report:

https://ept.ms/3B8HlsU

Babies:

https://ept.ms/3GJcxjI

https://ept.ms/3JfYt30


Stay tuned for our newsletter so you won’t miss out on our exclusive videos and private events.

Facts Matter is an Epoch Times show available on YouTube.

Follow Roman on Instagram: @epoch.times.roman

Listen to Podcasts:
iTunes Podcast: https://ept.ms/FactsMatterApplePodcast
Spotify Podcast: https://ept.ms/FactsMatterSpotifyPodcast
Google Podcast: https://ept.ms/FactsMatterGooglePodcast

Follow EpochTV on social media:

Facebook: https://www.facebook.com/EpochTVus
Twitter: https://twitter.com/EpochTVus
Rumble: https://rumble.com/c/EpochTV

Gettr: https://gettr.com/user/epochtv
Gab: https://gab.com/EpochTV
Telegram: https://t.me/EpochTV
Parler: https://parler.com/#/user/EpochTV

ntd newsletter icon
Sign up for NTD Daily
What you need to know, summarized in one email.
Stay informed with accurate news you can trust.
By registering for the newsletter, you agree to the Privacy Policy.
Comments